Publication | Open Access

Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers

Breast OncologySpecific ActivityMedicineRecurrence Risk ScorePathologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentBreast CancersOncologyRadiation OncologyTumor Microenvironment